JP2012529535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529535A5 JP2012529535A5 JP2012515123A JP2012515123A JP2012529535A5 JP 2012529535 A5 JP2012529535 A5 JP 2012529535A5 JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012529535 A5 JP2012529535 A5 JP 2012529535A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- alkoxy
- substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 264
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 131
- -1 —OH Chemical group 0.000 claims 74
- 125000003545 alkoxy group Chemical group 0.000 claims 56
- 125000005843 halogen group Chemical group 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 47
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 28
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 12
- 125000001624 naphthyl group Chemical group 0.000 claims 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 10
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 10
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000001041 indolyl group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002541 furyl group Chemical group 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- 125000002757 morpholinyl group Chemical group 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 235000010290 biphenyl Nutrition 0.000 claims 5
- 239000004305 biphenyl Substances 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000001207 fluorophenyl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 C*(C(*=C(C)N)=C(C(*)=C)C(*(C)(C)*)=O)c1ccc(C)c(C)c1 Chemical compound C*(C(*=C(C)N)=C(C(*)=C)C(*(C)(C)*)=O)c1ccc(C)c(C)c1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18641709P | 2009-06-12 | 2009-06-12 | |
| US61/186,417 | 2009-06-12 | ||
| PCT/US2010/038079 WO2010144647A1 (en) | 2009-06-12 | 2010-06-10 | Nicotinamide compounds useful as kinase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529535A JP2012529535A (ja) | 2012-11-22 |
| JP2012529535A5 true JP2012529535A5 (enExample) | 2013-06-27 |
Family
ID=42543320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515123A Pending JP2012529535A (ja) | 2009-06-12 | 2010-06-10 | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8586751B2 (enExample) |
| EP (1) | EP2440204B1 (enExample) |
| JP (1) | JP2012529535A (enExample) |
| CN (1) | CN102458402B (enExample) |
| ES (1) | ES2444777T3 (enExample) |
| WO (1) | WO2010144647A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| BR112012033770A2 (pt) | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
| WO2012061418A2 (en) * | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
| PT2718270T (pt) * | 2011-06-10 | 2022-07-29 | Merck Patent Gmbh | Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk |
| US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| WO2013099041A1 (ja) * | 2011-12-28 | 2013-07-04 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| EP2802576B1 (en) | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106641A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| JP6134376B2 (ja) * | 2012-03-16 | 2017-05-24 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2013157022A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| BR112015007217A2 (pt) * | 2012-10-19 | 2017-08-08 | Hoffmann La Roche | compostos e usos do composto |
| CN104903301B (zh) * | 2012-11-08 | 2017-08-29 | 百时美施贵宝公司 | 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
| CN104109127B (zh) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CN108715615B (zh) | 2013-09-13 | 2020-11-27 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CN104341388B (zh) * | 2013-10-16 | 2017-03-22 | 北京诺诚健华医药科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN105939998B (zh) * | 2013-10-21 | 2019-04-16 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| GB201319277D0 (en) * | 2013-10-31 | 2013-12-18 | Akthelia Pharmaceuticals | A new class of inducers of antimicrobial compounds |
| JP6345786B2 (ja) | 2013-12-05 | 2018-06-20 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼの阻害剤 |
| AR098991A1 (es) * | 2014-01-03 | 2016-06-22 | Bristol Myers Squibb Co | Compuestos de nicotinamida sustituida con heteroarilo |
| EA032356B1 (ru) * | 2014-03-17 | 2019-05-31 | Пфайзер Инк. | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| UY36371A (es) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec |
| EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN104672219A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途 |
| CN104672218A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途 |
| WO2016210036A1 (en) | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10294229B2 (en) | 2015-06-24 | 2019-05-21 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| JP6993056B2 (ja) | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ |
| CN116478166A (zh) | 2016-08-16 | 2023-07-25 | 百济神州(苏州)生物科技有限公司 | 一种化合物的晶型、其制备和用途 |
| DK3500299T3 (da) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer |
| MX390121B (es) | 2016-09-19 | 2025-03-20 | Mei Pharma Inc | Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas. |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| CA3062602A1 (en) | 2017-05-11 | 2018-11-15 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| CN110799543A (zh) | 2017-06-26 | 2020-02-14 | 百济神州有限公司 | 肝细胞癌的免疫治疗 |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| CN118955473A (zh) * | 2018-10-15 | 2024-11-15 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| US12378240B2 (en) | 2018-11-20 | 2025-08-05 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| JP7406264B2 (ja) | 2018-11-20 | 2023-12-27 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのシアノアリール－アニリン化合物 |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| KR20220035447A (ko) | 2019-07-18 | 2022-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물 |
| EP3999508B1 (en) | 2019-07-18 | 2023-08-30 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| ES2983263T3 (es) | 2019-08-06 | 2024-10-22 | Bristol Myers Squibb Co | Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4 |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| US12421230B2 (en) | 2020-02-03 | 2025-09-23 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors |
| CN111909053B (zh) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | 基于二芳胺单元的酰胺类衍生物及其制备方法和应用 |
| US20240360146A1 (en) * | 2021-07-01 | 2024-10-31 | Hangzhou Healzen Therapeutics Co., Ltd. | Bruton's tyrosine kinase and mutant degrader, composition and application thereof |
| US12377106B2 (en) | 2021-10-26 | 2025-08-05 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK |
| MX2024008480A (es) * | 2022-01-07 | 2024-07-15 | Chugai Pharmaceutical Co Ltd | Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2). |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132603C (enExample) | 1964-08-29 | |||
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| US5104877A (en) | 1991-02-25 | 1992-04-14 | Abbott Laboratories | Psoriasis treatment |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US5972975A (en) | 1995-12-08 | 1999-10-26 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| ZA977427B (en) | 1996-09-04 | 1998-03-02 | Dainippon Pharmaceutical Co | 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same. |
| EP1028950B1 (en) | 1997-10-28 | 2003-05-02 | Warner-Lambert Company LLC | 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
| ES2308821T3 (es) | 1997-12-15 | 2008-12-01 | Astellas Pharma Inc. | Nuevos derivados de pirimidin-5-carboxamida. |
| IL144717A0 (en) | 1999-02-24 | 2002-06-30 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| DE60017898T2 (de) * | 1999-06-09 | 2006-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | Neuartige heterocyclische carboxamidderivate |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| KR100532546B1 (ko) | 1999-09-16 | 2005-12-01 | 다나베 세이야꾸 가부시키가이샤 | 방향족 질소 함유 6-원 고리 화합물 |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| AU2002213466A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | ４−アリールピリジン誘導体 |
| JP4178816B2 (ja) | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
| AU2003272324A1 (en) | 2002-09-10 | 2004-04-30 | Scios Inc. | INHIBITORS OF TFGBeta |
| US20040116479A1 (en) | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| ES2285409T3 (es) | 2003-01-16 | 2007-11-16 | Sb Pharmco Puerto Rico Inc | Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf. |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US7459460B2 (en) | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| EP1678146A1 (en) | 2003-10-23 | 2006-07-12 | Pharmacia Corporation | Pyrimidine compounds for the treatment of inflammation |
| US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| CN101676285A (zh) | 2004-03-30 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 用作jak和其它蛋白激酶抑制剂的氮杂吲哚 |
| CA2564355C (en) | 2004-05-07 | 2012-07-03 | Amgen Inc. | Protein kinase modulators and method of use |
| US20050288502A1 (en) | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| AU2005289426A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| JP2008516973A (ja) | 2004-10-15 | 2008-05-22 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| BRPI0517619A (pt) | 2004-11-10 | 2008-10-14 | Cgi Pharmaceuticals Inc | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| WO2006088919A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| EP1863766B1 (en) | 2005-03-10 | 2015-05-20 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US7468382B2 (en) | 2005-03-28 | 2008-12-23 | Boehringer Ingelheim International Gmbh | Pyridine derivatives useful as inhibitors of PKC-theta |
| EP1879564B1 (en) | 2005-04-07 | 2009-12-23 | Astrum Therapeutics Pty, Ltd. | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
| AU2006247482A1 (en) | 2005-05-13 | 2006-11-23 | Lexicon Pharmaceuticals, Inc. | Multicyclic compounds and methods of their use |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| US20090203744A1 (en) | 2005-07-29 | 2009-08-13 | Pande Y Surendrakumar Satyanarayan | Novel pyridine derivatives |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20090131420A1 (en) | 2005-10-07 | 2009-05-21 | Pandey Surendrakumar S | Novel Heterocyclic Analogs of Biphenyl Ethers |
| EP2388258A1 (de) | 2005-10-19 | 2011-11-23 | Grünenthal GmbH | Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| JP5169220B2 (ja) | 2005-11-30 | 2013-03-27 | アステラス製薬株式会社 | ２−アミノベンズアミド誘導体 |
| EP1984353B1 (en) | 2006-01-23 | 2015-12-30 | Amgen, Inc | Aurora kinase modulators and method of use |
| US20070208164A1 (en) | 2006-02-27 | 2007-09-06 | Wyeth | Methods of synthesizing radiolabeled 3-cyano[14C]quinolines |
| CN101484449A (zh) | 2006-04-28 | 2009-07-15 | 艾维克有限公司 | 整合酶抑制剂-3 |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2008013499A (ja) * | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | ５−シアノニコチンアミド誘導体 |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US7939548B2 (en) | 2006-08-02 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US20090318389A1 (en) | 2006-08-04 | 2009-12-24 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1 phosphate receptor |
| US20080076800A1 (en) | 2006-08-24 | 2008-03-27 | Huang Kenneth H | Benzene, Pyridine, and Pyridazine Derivatives |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| JPWO2008044713A1 (ja) | 2006-10-10 | 2010-02-18 | 日本農薬株式会社 | 置換ピリジンカルボン酸アニリド誘導体又はその塩類、及び農園芸用薬剤並びにその使用方法 |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US7915287B2 (en) | 2006-12-20 | 2011-03-29 | Amgen Inc. | Substituted heterocycles and methods of use |
| FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| AU2008314632B2 (en) | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
-
2010
- 2010-06-10 EP EP10724657.1A patent/EP2440204B1/en not_active Not-in-force
- 2010-06-10 ES ES10724657.1T patent/ES2444777T3/es active Active
- 2010-06-10 US US13/377,157 patent/US8586751B2/en active Active
- 2010-06-10 WO PCT/US2010/038079 patent/WO2010144647A1/en not_active Ceased
- 2010-06-10 CN CN2010800346423A patent/CN102458402B/zh not_active Expired - Fee Related
- 2010-06-10 JP JP2012515123A patent/JP2012529535A/ja active Pending